New York, March 25, 2025—Global Action to End Smoking is pleased to announce that Doris Taylor, PhD, Hon D. Sc. FAHA, FACC, FESC, FAIMBE, has joined the organization’s Board of Directors.
As a world-renowned scientist, Dr. Taylor’s presence on Global Action’s board supports the organization’s mission to accelerate the highest quality research and other efforts to end the worldwide smoking epidemic.
Doris’ commitment to health and medical research is evidenced by her trailblazing career. Her scientific expertise will help our organization lead the way to a world in which death and disease related to smoking are a thing of the past.”
Dr. Taylor is an expert in regenerative medicine and tissue engineering. She is the co-founder and CEO of Organamet, Bio, Inc., a company dedicated to saving lives through bioengineered, personalized interventions in cardiology. Her pioneering research has led to dozens of scientific breakthroughs that have been recognized in the scientific community through top-tier journal publications, patents, and invention disclosures. Dr. Taylor is a Fellow with the American Heart Association, the American College of Cardiology, and the European Society of Cardiology, the American Institute for Medical and Biological Engineering, and a senior member of the National Academy of Inventors.
“As a scientist, I always follow the data. In this case, the data clearly shows that to improve global health, we must embrace harm reduction in tobacco control efforts to aid the one billion adults who smoke while protecting youth. It’s a pleasure to work with Global Action as it pioneers this approach while accelerating research to save lives.”
Dr. Taylor completed her PhD in pharmacology from UT Southwestern Medical Center, followed by a postdoctoral fellowship in immunology and molecular biology at the Albert Einstein College of Medicine. She is based in Alabama.